(Reuters) - CHICAGO, June 25 - CryoCor Inc.
failed to demonstrate the safety and long-term
effectiveness of its experimental treatment for a form of
abnormal heart rhythm, U.S. regulators said on Monday, sending
the medical device maker's shares down nearly 35 percent.
A U.S. Food and Drug Administration advisory panel will
consider on Wednesday if the device should be approved for sale
in the United States.
Read more at Reuters.com Government Filings News
failed to demonstrate the safety and long-term
effectiveness of its experimental treatment for a form of
abnormal heart rhythm, U.S. regulators said on Monday, sending
the medical device maker's shares down nearly 35 percent.
A U.S. Food and Drug Administration advisory panel will
consider on Wednesday if the device should be approved for sale
in the United States.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment